Table 2 The relationships between NLR and mortality in cancer participants.

From: Neutrophil-to-lymphocyte ratio as a predictor of cardiovascular mortality in cancer survivors

Mortality

NLR

Lower NLR (n = 3138)

Higher NLR (n = 1836)

HR

95% CI

P value

HR

HR

95% CI

P value

All-cause mortality

 Unadjusted

1.21

1.15–1.25

 < 0.001

Ref

2.02

1.73–2.36

 < 0.001

 Model 1

1.11

1.07–1.14

 < 0.001

Ref

1.44

1.27–1.63

 < 0.001

 Model 2

1.10

1.07–1.13

 < 0.001

Ref

1.38

1.22–1.55

 < 0.001

Cardiovascular mortality

 Unadjusted

1.23

1.16–1.31

 < 0.001

Ref

2.72

2.11–3.52

 < 0.001

 Model 1

1.14

1.08–1.21

 < 0.001

Ref

1.74

1.36–2.22

 < 0.001

 Model 2

1.12

1.06–1.18

 < 0.001

Ref

1.63

1.27–2.09

 < 0.001

Cancer-specific mortality

 Unadjusted

1.15

1.09–1.21

 < 0.001

Ref

1.92

1.54–2.41

 < 0.001

 Model 1

1.07

1.01–1.12

0.014

Ref

1.48

1.19–1.86

 < 0.001

 Model 2

1.06

1.01–1.12

0.023

Ref

1.45

1.17–1.79

 < 0.001

  1. Survey sample weights were taken into consideration in the Cox models accompanying the NHANES data. Model 1 was adjusted for gender, age, race, marital status, educational level, family income level, smoke history. Model 2 was additionally adjusted for the presence of comorbidities such as DM, CHD, HF, HBP, high cholesterol, stroke, chronic bronchitis and liver diseases.
  2. HF heart failure, CHD coronary heart disease, HBP hypertension, DM Diabetes.
Back to article page